Navigation Links
The ECNP consensus statement on bipolar depression
Date:7/8/2008

Bipolar disorder is one of the most complex and challenging mental disorder in the spectrum. Bipolar disorder is typically associated with considerable acute and longterm treatment needs and may be associated in the course of illness with times of tremendous social burden for both the individual and family. It is typically referred to as an episodic, yet lifelong and clinically severe mood disorder. The disorder is called bipolar, because depressive and manic mood episodes alternate in the course of illness. Because the manic part may be sometimes less impairing and disabling, clinicians differentiate the less severe expression with euphoria and/or extreme irritability called hypomania as Bipolar II as opposed to the more dramatic and severe mania (called Bipolar I disorder).

The long-term course of bipolar disorder is usually dominated by depressive rather than (hypo)manic symptoms, and disease onset tends to be earlier than in patients showing only major depression. A major challenge in the treatment of patients with mood disorders is the distinction between bipolar and unipolar depression from early on, since these conditions may require different types of treatment. Unfortunately, all too often patients with bipolar depression remain untreated or improperly treated. Over the last 10-15 years, there has been an increasing awareness and knowledge about bipolar disorder reflecting the explosion on all fronts in the biomedical literature. Everybody struggles to keep up to.

To take account of the accumulating evidence and experience, the European College of Neuropsychopharmacology (ECNP) recently published a consensus statement that provides an expert summary of state-of-the-art knowledge concerning all aspects of bipolar depression, and broader issues of bipolarity. The highlights of this statement will be presented by the renowned British researcher Guy M. Goodwin from the University Department of Psychiatry, Warneford Hospital, Oxford. The apparent differences between unipolar and bipolar depression arise in diagnosis and epidemiology, bipolar depression in children as well as adults, the use of rating scales, and finally treatment studies to optimize pharmacotherapy and clinical outcome.


'/>"/>

Contact: Sonja Mak
s.mak@update.europe.at
43-140-55734
European College of Neuropsychopharmacology
Source:Eurekalert

Related medicine news :

1. Journal of Ultrasound In Medicine features bioeffects consensus report
2. National Quality Forum Endorses Consensus Standards for Quality of Hospital Care
3. CEOs From Multiple Health Industries Announce Consensus Plan to Reform U.S. Health Care
4. Global Consensus on Mercury: Scientists Defend Science Journalists
5. Curbing worlds most fatal diseases: consensus created by health experts offers global prescription
6. Health Information Exchange Consensus Conference Reinforces Key Role of State-Level Entities
7. Polyanalgesic Consensus Panels New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain
8. eHealth Initiative Releases Blueprint Representing Consensus on an Action Plan for Transforming U.S. Healthcare Using Health IT
9. National Quality Forum Issues First Consensus Standards for the Treatment of Substance Use Conditions
10. Blue Cross and Blue Shield Association Statement: Health Care America Now
11. Anthem Blue Cross Statement on Settlement Discussions with the California Department of Managed Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... My T Chai, ... its products are now available for purchase on RevNutrition.com, a popular website specializing in ... first produced and popularized in ancient India and Siam. It spread across Asia and ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading ... today announced that Kyle Allain has joined the company as Vice President and ... operations, including provider, payor and managed care solutions. , A seasoned executive ...
(Date:4/24/2017)... ... 24, 2017 , ... In 2017, up to 78,000 new ... of them will be malignant.(1) As research into precision medicine continues, both patients ... in the diagnosis and treatment of brain tumors. Healthcare facilities that are already ...
(Date:4/24/2017)... ... 2017 , ... Rod Burkett, CEO of Gardant Management Solutions, was recently featured ... at the forefront of Gardant since it was founded in 1999. His drive and ... of more than 40 new senior living communities. With his leadership, Gardant has grown ...
(Date:4/24/2017)... ... ... As a former supermodel known for her timeless beauty, Joan Severance knows ... is that she put all the words in her new book, "Manifest Your Mate: ... and sparkling sense of humor have inspired her to write a book on how ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-na├»ve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... and Gynecology markets with innovative and proprietary products, will ... 31, 2017 after the market close on Tuesday, May ... a conference call and webcast to discuss its financial ... at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
(Date:4/18/2017)...  Astute Medical, Inc., developer of biomarkers for better ... at the 2017 National Kidney Foundation (NKF) Spring ... April 22. Physicians will present data on two biomarkers, ... for acute kidney injury (AKI) during the management of ... Elevated levels of TIMP-2 and IGFBP-7 have been ...
Breaking Medicine Technology: